Drugmakers Seek Clarifications of FDA’s Interchangeability Guidance

Generic Line
More drugmakers have weighed in on the FDA’s draft guidance on biosimilar interchangeability, urging the agency to make clear the designation does not mean a product is superior in terms of safety or efficacy.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00